2021-10-12
In autumn 2021 Poltreg will present the results of clinical trials in several important scientific meetings:
October 25-26 – 3 Health of Poles Congress
http://kongres-zdrowiepolakow.pl/
November 8-10 – VIII 8th EUROBIOTECH Congress, Kraków
https://www.eurobiotech.krakow.pl/gb/
November 25-26 – XV Congrés de la Societat Catalana d’Immunologia, Barcelona (online)
Facebook:
https://www.facebook.com/SCImmunologia
web:
https://www.academia.cat/files/425-19089-DOCUMENT/PostercongrsSCI2021.pdf
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
2024-06-25
PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk
2024-06-24
Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes
2024-06-13
PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment
2024-05-14
PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered
